Literature DB >> 26771497

Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.

Richard Marcotte1, Azin Sayad1, Kevin R Brown2, Felix Sanchez-Garcia3, Jüri Reimand2, Maliha Haider1, Carl Virtanen1, James E Bradner4, Gary D Bader2, Gordon B Mills5, Dana Pe'er3, Jason Moffat6, Benjamin G Neel7.   

Abstract

Large-scale genomic studies have identified multiple somatic aberrations in breast cancer, including copy number alterations and point mutations. Still, identifying causal variants and emergent vulnerabilities that arise as a consequence of genetic alterations remain major challenges. We performed whole-genome small hairpin RNA (shRNA) "dropout screens" on 77 breast cancer cell lines. Using a hierarchical linear regression algorithm to score our screen results and integrate them with accompanying detailed genetic and proteomic information, we identify vulnerabilities in breast cancer, including candidate "drivers," and reveal general functional genomic properties of cancer cells. Comparisons of gene essentiality with drug sensitivity data suggest potential resistance mechanisms, effects of existing anti-cancer drugs, and opportunities for combination therapy. Finally, we demonstrate the utility of this large dataset by identifying BRD4 as a potential target in luminal breast cancer and PIK3CA mutations as a resistance determinant for BET-inhibitors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26771497      PMCID: PMC4724865          DOI: 10.1016/j.cell.2015.11.062

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  68 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.

Authors:  Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

3.  Integration of genomic data enables selective discovery of breast cancer drivers.

Authors:  Félix Sanchez-Garcia; Patricia Villagrasa; Junji Matsui; Dylan Kotliar; Verónica Castro; Uri-David Akavia; Bo-Juen Chen; Laura Saucedo-Cuevas; Ruth Rodriguez Barrueco; David Llobet-Navas; Jose M Silva; Dana Pe'er
Journal:  Cell       Date:  2014-11-26       Impact factor: 41.582

4.  Evidence for the ubiquitin protease UBP43 as an antineoplastic target.

Authors:  Yongli Guo; Fadzai Chinyengetere; Andrey V Dolinko; Alexandra Lopez-Aguiar; Yun Lu; Fabrizio Galimberti; Tian Ma; Qing Feng; David Sekula; Sarah J Freemantle; Angeline S Andrew; Vincent Memoli; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2012-07-02       Impact factor: 6.261

5.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

Authors:  Christopher A French; Isao Miyoshi; Ichiro Kubonishi; Holcombe E Grier; Antonio R Perez-Atayde; Jonathan A Fletcher
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

6.  Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer.

Authors:  Nasser Ghaly Yousif; Fadhil G Al-Amran; Najah Hadi; Jillen Lee; Jonthan Adrienne
Journal:  Cytokine       Date:  2012-10-26       Impact factor: 3.861

7.  The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.

Authors:  J M Bosher; T Williams; H C Hurst
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

8.  A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.

Authors:  Fabio Petrocca; Gabriel Altschuler; Shen Mynn Tan; Marc L Mendillo; Haoheng Yan; D Joseph Jerry; Andrew L Kung; Winston Hide; Tan A Ince; Judy Lieberman
Journal:  Cancer Cell       Date:  2013-08-12       Impact factor: 31.743

Review 9.  Epithelial growth factor receptor-activated nuclear factor κB signaling and its role in epithelial growth factor receptor-associated tumors.

Authors:  Deng Pan; Xin Lin
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

10.  Modeling precision treatment of breast cancer.

Authors:  Anneleen Daemen; Obi L Griffith; Laura M Heiser; Nicholas J Wang; Oana M Enache; Zachary Sanborn; Francois Pepin; Steffen Durinck; James E Korkola; Malachi Griffith; Joe S Hur; Nam Huh; Jongsuk Chung; Leslie Cope; Mary Jo Fackler; Christopher Umbricht; Saraswati Sukumar; Pankaj Seth; Vikas P Sukhatme; Lakshmi R Jakkula; Yiling Lu; Gordon B Mills; Raymond J Cho; Eric A Collisson; Laura J van't Veer; Paul T Spellman; Joe W Gray
Journal:  Genome Biol       Date:  2013       Impact factor: 13.583

View more
  170 in total

1.  Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.

Authors:  Xiarong Shi; Valia T Mihaylova; Leena Kuruvilla; Fang Chen; Stephen Viviano; Massimiliano Baldassarre; David Sperandio; Ruben Martinez; Peng Yue; Jamie G Bates; David G Breckenridge; Joseph Schlessinger; Benjamin E Turk; David A Calderwood
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

2.  Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Authors:  Jun Li; Wei Zhao; Rehan Akbani; Wenbin Liu; Zhenlin Ju; Shiyun Ling; Christopher P Vellano; Paul Roebuck; Qinghua Yu; A Karina Eterovic; Lauren A Byers; Michael A Davies; Wanleng Deng; Y N Vashisht Gopal; Guo Chen; Erika M von Euw; Dennis Slamon; Dylan Conklin; John V Heymach; Adi F Gazdar; John D Minna; Jeffrey N Myers; Yiling Lu; Gordon B Mills; Han Liang
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

3.  PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.

Authors:  Kanak Raina; Jing Lu; Yimin Qian; Martha Altieri; Deborah Gordon; Ann Marie K Rossi; Jing Wang; Xin Chen; Hanqing Dong; Kam Siu; James D Winkler; Andrew P Crew; Craig M Crews; Kevin G Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

4.  A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.

Authors:  Xiaodong Feng; Nadia Arang; Damiano Cosimo Rigiracciolo; Joo Sang Lee; Huwate Yeerna; Zhiyong Wang; Simone Lubrano; Ayush Kishore; Jonathan A Pachter; Gabriele M König; Marcello Maggiolini; Evi Kostenis; David D Schlaepfer; Pablo Tamayo; Qianming Chen; Eytan Ruppin; J Silvio Gutkind
Journal:  Cancer Cell       Date:  2019-02-14       Impact factor: 31.743

5.  Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.

Authors:  Özge Saatci; Simone Borgoni; Özge Akbulut; Selvi Durmuş; Umar Raza; Erol Eyüpoğlu; Can Alkan; Aytekin Akyol; Özgür Kütük; Stefan Wiemann; Özgür Şahin
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

6.  Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions.

Authors:  Christopher J Lord; Niall Quinn; Colm J Ryan
Journal:  Elife       Date:  2020-05-28       Impact factor: 8.140

7.  Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets.

Authors:  Prson Gautam; Alok Jaiswal; Tero Aittokallio; Hassan Al-Ali; Krister Wennerberg
Journal:  Cell Chem Biol       Date:  2019-05-02       Impact factor: 8.116

8.  FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion.

Authors:  Joanna Stanicka; Leonie Rieger; Sandra O'Shea; Orla Cox; Michael Coleman; Ciara O'Flanagan; Barbara Addario; Nuala McCabe; Richard Kennedy; Rosemary O'Connor
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

9.  Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development.

Authors:  Pan Tang; Jifa Zhang; Jie Liu; Cheng-Ming Chiang; Liang Ouyang
Journal:  J Med Chem       Date:  2021-02-22       Impact factor: 7.446

10.  Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer.

Authors:  Nathaniel W Mabe; Douglas B Fox; Ryan Lupo; Amy E Decker; Stephanie N Phelps; J Will Thompson; James V Alvarez
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.